Imugene (ASX:IMU) | JMM & éthica Capital Innovation & Investment Insights | May 2024

Imugene's CEO & Managing Director Leslie Chong recently delivered a dynamic 'stand-up and pitch' presentation to investors in Sydney. In her talk, she briefly recounted her journey to leading Imugene's team, which collectively boasts over 150 years of experience. She shared updates on the Phase 1B Study, the sale of our manufacturing facility in North Carolina, and our oncarlytic Phase One study. This latter study is showing remarkable response rates, and the FDA has granted us fast-track status.
🔗 Stay Connected: www.imugene.com
Follow us on Twitter: @TeamImugene
Connect with us on LinkedIn: / imugene
Explore more on our website: www.imugene.com
#Imugene #CancerResearch #Biotech #Immunotherapy #Oncology #AusBiz

[@JoyceNegrineyoga]

Thank You Imugene, your groundbreaking advances are brilliant! Congratulations!